Immune cell expression patterns of CD39/CD73 ectonucleotidases in rodent models of cardiac arrest and resuscitation

被引:2
|
作者
Aoki, Tomoaki [1 ]
Wong, Vanessa [1 ,2 ]
Yin, Tai [1 ]
Nakamura, Eriko [1 ]
Endo, Yusuke [1 ]
Hayashida, Kei [1 ]
Robson, Simon C. [3 ]
Nandurkar, Harshal [4 ]
Diamond, Betty [5 ]
Kim, Sun Jung [5 ]
Murao, Atsushi [6 ]
Wang, Ping [6 ]
Becker, Lance B. [1 ,7 ]
Shinozaki, Koichiro [1 ,5 ,7 ,8 ]
机构
[1] Northwell Hlth, Feinstein Inst Med Res, Dept Biostat, Manhasset, NY 11552 USA
[2] SUNY Downstate Med Ctr, Brooklyn, NY USA
[3] Beth Israel Deaconess Med Ctr, Harvard Med Sch, Dept Anesthesia, Boston, MA USA
[4] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia
[5] Inst Mol Med, Feinstein Inst Med Res, Northwell Hlth, Manhasset, NY 11552 USA
[6] Northwell Hlth, Feinstein Inst Med Res, Ctr Immunol & Inflammat, Manhasset, NY USA
[7] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Emergency Med, Hempstead, NY 11552 USA
[8] Kindai Univ, Fac Med, Dept Emergency & Crit Care Med, Osaka, Japan
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
rodent; monocytes; T cells; B cells; heart arrest; cardiopulmonary resuscitation; ischemia; reperfusion injury; CARDIOPULMONARY-RESUSCITATION; NEURONAL INJURY; T-LYMPHOCYTES; BRAIN; ISCHEMIA; NEUROINFLAMMATION; INFLAMMATION; MACROPHAGES; IMMUNOLOGY; RESPONSES;
D O I
10.3389/fimmu.2024.1362858
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Cardiac arrest (CA) is a significant public health concern. There is the high imminent mortality and survival in those who are resuscitated is substantively compromised by the post-CA syndrome (PCAS), characterized by multiorgan ischemia-reperfusion injury (IRI). The inflammatory response in PCAS is complex and involves various immune cell types, including lymphocytes and myeloid cells that have been shown to exacerbate organ IRI, such as myocardial infarction. Purinergic signaling, as regulated by CD39 and CD73, has emerged as centrally important in the context of organ-specific IRI. Hence, comprehensive understanding of such purinergic responses may be likewise imperative for improving outcomes in PCAS. Methods: We have investigated alterations of immune cell populations after CA by utilizing rodent models of PCAS. Blood and spleen were collected after CA and resuscitation and underwent flow cytometry analysis to evaluate shifts in CD3(+)CD4(+) helper T cells, CD3(+)CD8a(+) cytotoxic T cells, and CD4/CD8a ratios. We then examined the expression of CD39 and CD73 across diverse cell types, including myeloid cells, T lymphocytes, and B lymphocytes. Results: In both rat and mouse models, there were significant increases in the frequency of CD3(+)CD4(+) T lymphocytes in PCAS (rat, P < 0.01; mouse, P < 0.001), with consequently elevated CD4/CD8a ratios in whole blood (both, P < 0.001). Moreover, CD39 and CD73 expression on blood leukocytes were markedly increased (rat, P < 0.05; mouse, P < 0.01 at 24h). Further analysis in the experimental mouse model revealed that CD11b(+) myeloid cells, with significant increase in their population (P < 0.01), had high level of CD39 (88.80 +/- 2.05 %) and increased expression of CD73 (P < 0.05). CD19(+) B lymphocytes showed slight increases of CD39 (P < 0.05 at 2h) and CD73 (P < 0.05 at 2h), while, CD3(+) T lymphocytes had decreased levels of them. These findings suggested a distinct patterns of expression of CD39 and CD73 in these specific immune cell populations after CA. Conclusions: These data have provided comprehensive insights into the immune response after CA, highlighting high-level expressions of CD39 and CD73 in myeloid cells.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] The role of CD39 and CD73 expressed by regulatory T cell in the pathogenesis of asthma in mice
    Dai, Ranran
    Wang, Linlin
    Shi, Guochao
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [42] Antagonists of CD39 and CD73 potentiate doxycycline repositioning to induce a potent antitumor immune response
    Dalai, Parameswar
    Shah, Dhruvi
    Shah, Jigna
    Soni, Kinal
    Mohanty, Aditya
    Thanki, Kavya
    Dave, Heena
    Agrawal-Rajput, Reena
    CELLULAR SIGNALLING, 2025, 125
  • [43] Variability in CD39 and CD73 protein levels in uveal melanoma patients
    Harou, Olivier
    Cros-Perrial, Emeline
    Alix, Eudeline
    Callet-Bauchu, Evelyne
    Bertheau, Charlotte
    Dumontet, Charles
    Devouassoux-Shisheboran, Mojgan
    Jordheim, Lars Petter
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2022, 41 (11): : 1099 - 1108
  • [44] CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
    Battastini, Ana Maria Oliveira
    Figueiro, Fabricio
    Leal, Daniela Bitencourt Rosa
    Doleski, Pedro Henrique
    Schetinger, Maria Rosa Chitolina
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [45] DYSREGULATED BALANCE OF CD39 AND CD73 CELLS IN DIABETIC ESRD PATIENTS
    Jo, Young-Il
    Seo, Eun-Hye
    Kim, Joo-Dong
    Lee, Seung-Hyun
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 173 - 173
  • [46] CD39/CD73/A2AR pathway and cancer immunotherapy
    Xia, Chenglai
    Yin, Shuanghong
    To, Kenneth K. W.
    Fu, Liwu
    MOLECULAR CANCER, 2023, 22 (01)
  • [47] CD39/CD73/A2AR pathway and cancer immunotherapy
    Chenglai Xia
    Shuanghong Yin
    Kenneth K. W. To
    Liwu Fu
    Molecular Cancer, 22
  • [48] CD39/CD73 Expressing Exosomes Protect Against Arterial Thrombosis
    Covarrubias, Roman
    Snoek, Susanne A.
    Zhong, Lin
    Broekstra, Niels
    Finn, Jonathan D.
    Gumina, Richard J.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2017, 37
  • [49] Monitoring the activities of ectonucleotidases CD39 and CD73 and their specific modulation by antibodies and small molecules using homogenous HTS formatted platform
    Goueli, Said A.
    Hsiao, Kevin
    Zegzouti, Hicham
    CANCER RESEARCH, 2020, 80 (16)
  • [50] Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response
    Ortiz, Maria Angels
    Diaz-Torne, Cesar
    De Agustin, Juan Jose
    Estrada, Paula
    Reina, Delia
    Hernandez, Maria Victoria
    Sang, Hye
    Zamora, Carlos
    Canto, Elisabet
    Corominas, Hector
    Vidal, Silvia
    Celec, Peter
    BIOMOLECULES, 2024, 14 (01)